K
Kaj Metsärinne
Researcher at Turku University Hospital
Publications - 48
Citations - 5799
Kaj Metsärinne is an academic researcher from Turku University Hospital. The author has contributed to research in topics: Kidney disease & Renal function. The author has an hindex of 18, co-authored 42 publications receiving 4974 citations. Previous affiliations of Kaj Metsärinne include University of Turku & University of Paris.
Papers
More filters
Journal ArticleDOI
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom,Stuart J. Connolly,Jackie Bosch,Gilles R. Dagenais,Robert G. Hart,Olga Shestakovska,Rafael Diaz,Marco Alings,Eva Lonn,Sonia S. Anand,Petr Widimsky,Masatsugu Hori,Alvaro Avezum,Leopoldo S. Piegas,Kelley R. Branch,Jeffrey L. Probstfield,Deepak L. Bhatt,Jun Zhu,Yan Liang,Aldo P. Maggioni,Patricio Lopez-Jaramillo,Martin O'Donnell,Ajay K. Kakkar,Keith A.A. Fox,Alexander Parkhomenko,Georg Ertl,Stefan Störk,Matyas Keltai,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Peter Verhamme,Dragos Vinereanu,Jae-Hyung Kim,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,P. Gabriel Steg,Kaj Metsärinne,Nancy Cook Bruns,Frank Misselwitz,Edmond Chen,Darryl P. Leong,Salim Yusuf +48 more
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Journal ArticleDOI
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
Johannes F.E. Mann,Roland E. Schmieder,Matthew J. McQueen,Leanne Dyal,Helmut Schumacher,Janice Pogue,Xingyu Wang,Aldo P. Maggioni,Andrzej Budaj,Suphachai Chaithiraphan,Kenneth Dickstein,Matyas Keltai,Kaj Metsärinne,Ali Oto,Alexander Parkhomenko,Leopoldo S. Piegas,Tage Lysbo Svendsen,Koon K. Teo,Salim Yusuf +18 more
TL;DR: In people at high vascular risk, telmisartan's effects on major renal outcomes are similar to ramipril, and although combination therapy reduces proteinuria to a greater extent than monotherapy, overall it worsens major renal outcome.
Journal Article
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study) : a multicentre, randomised, double-blind, controlled trial. Commentary
Pantelis Sarafidis,George L. Bakris,Johannes F.E. Mann,Roland E. Schmieder,Matthew J. McQueen,Leanne Dyal,Helmut Schumacher,Janice Pogue,Xingyu Wang,Aldo P. Maggioni,Andrzej Budaj,Suphachai Chaithiraphan,Kenneth Dickstein,Matyas Keltai,Kaj Metsärinne,All Oto,Alexander Parkhomenko,Leopoldo S. Piegas,Tage Lysbo Svendsen,Koon K. Teo,Salim Yusuf +20 more
TL;DR: In this article, the authors investigated the renal effects of Ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage.
Journal ArticleDOI
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Paul Moayyedi,John W. Eikelboom,Jackie Bosch,Stuart J. Connolly,Leanne Dyal,Olga Shestakovska,Darryl P. Leong,Sonia S. Anand,Stefan Störk,Kelley R. Branch,Deepak L. Bhatt,Peter Verhamme,Martin O'Donnell,Aldo P. Maggioni,Eva Lonn,Leopoldo S. Piegas,Georg Ertl,Matyas Keltai,Nancy Cook Bruns,Eva Muehlhofer,Gilles R. Dagenais,Jae-Hyung Kim,Masatsugu Hori,P. Gabriel Steg,Robert G. Hart,Rafael Diaz,Marco Alings,Petr Widimsky,Alvaro Avezum,Jeffrey L. Probstfield,Jun Zhu,Yan Liang,Patricio Lopez-Jaramillo,Ajay K. Kakkar,Alexander Parkhomenko,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Tomek J. Guzik,Dragos Vinereanu,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,Kaj Metsärinne,Keith A.A. Fox,Salim Yusuf +50 more
TL;DR: In a large placebo-controlled randomized trial, it is found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections.
Journal ArticleDOI
Asbestos exposure as a risk factor for retroperitoneal fibrosis
Toomas Uibu,Panu Oksa,Anssi Auvinen,Eero Honkanen,Kaj Metsärinne,Heikki Saha,Jukka Uitti,P. Roto +7 more
TL;DR: The results show that occupational asbestos exposure is an important causal factor for RPF and for patients with work-related asbestos exposure, RPF should be considered an occupational disease.